## **Catherine Le Berre**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2933321/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ulcerative colitis. Nature Reviews Disease Primers, 2020, 6, 74.	30.5	678
2	Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology, 2020, 158, 76-94.e2.	1.3	335
3	Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. New England Journal of Medicine, 2021, 385, 1302-1315.	27.0	137
4	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. Clinical Gastroenterology and Hepatology, 2020, 18, 14-23.	4.4	108
5	JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?. Gut, 2019, 68, 1893-1899.	12.1	100
6	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology, 2021, 160, 1452-1460.e21.	1.3	68
7	Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy, 2020, 20, 363-378.	3.1	58
8	Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. Journal of Crohn's and Colitis, 2019, 13, 1569-1577.	1.3	43
9	Small bowel capsule endoscopy and treat-to-target in Crohn's disease: A systematic review. World Journal of Gastroenterology, 2019, 25, 4534-4554.	3.3	35
10	Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy. Clinical Gastroenterology and Hepatology, 2019, 17, 794-796.	4.4	33
11	Impact of inflammatory bowel diseases on working life: A French nationwide survey. Digestive and Liver Disease, 2019, 51, 961-966.	0.9	27
12	VALIDation of the IBD-Disk Instrument for Assessing Disability in Inflammatory Bowel Diseases in a French Cohort: The VALIDate Study. Journal of Crohn's and Colitis, 2020, 14, 1512-1523.	1.3	27
13	Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology, 2022, 162, 1424-1438.	1.3	26
14	Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Digestive and Liver Disease, 2020, 52, 281-288.	0.9	17
15	A Magnetic Resonance Imaging Index to Predict Crohn's Disease Postoperative Recurrence: The MONITOR Index. Clinical Gastroenterology and Hepatology, 2022, 20, e1040-e1049.	4.4	16
16	Multi-expert annotation of Crohn's disease images of the small bowel for automatic detection using a convolutional recurrent attention neural network. Endoscopy International Open, 2021, 09, E1136-E1144.	1.8	13
17	Crohn's-like acute severe colitis associated with Hermansky-Pudlak syndrome: A case report. World Journal of Gastroenterology, 2019, 25, 1031-1036.	3.3	8
18	T cells show preferential adhesion to enteric neural cells in culture and are close to neural cells in the myenteric ganglia of Crohn's patients. Journal of Neuroimmunology, 2020, 349, 577422.	2.3	5

CATHERINE LE BERRE

#	Article	IF	CITATIONS
19	Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early�. Digestive Diseases and Sciences, 2019, 64, 3035-3037.	2.3	3
20	Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations. World Journal of Gastroenterology, 2020, 26, 4343-4355.	3.3	3
21	Will the Placebo Effect Disappear With New Targets For Treatment of Inflammatory Bowel Diseases?. Clinical Gastroenterology and Hepatology, 2020, 18, 1030-1032.	4.4	1
22	Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study. Digestive Diseases and Sciences, 2022, , 1.	2.3	1
23	Development of a new index to assess small bowel inflammation severity in Crohn's disease using Magnetic Resonance enterography. Crohn's & Colitis 360, 0, , .	1.1	0